Investigating the Activity of Indole-2-on Derivative Src Kinase Inhibitors Against Chronic Myeloid Leukemia Cells

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Src family tyrosine kinases are implicated in Bcr-Abl-induced leukemogenesis.
• Src kinase inhibitors demonstrate selectivity against chronic myeloid leukemia.

Purpose of the Study:

• To evaluate indole derivatives (C-1, C-2, C-3) as potential inhibitors of chronic myeloid leukemia.
• To assess the efficacy of these compounds against Bcr-Abl kinase and related leukemic cell lines.

Main Methods:

• Assessed cell viability, antiproliferative, and antioxidant effects of indole derivatives on K562 and R/K562 cells.
• Determined Bcr-Abl kinase inhibition profiles and compared efficacy with dasatinib and imatinib.
• Conducted docking studies to confirm kinase inhibition and calculated drug-like properties.

Main Results:

• Indole derivatives reduced Bcr/Abl levels and inhibited cell proliferation, indicating antileukemic activity linked to Bcr/Abl expression.
• Docking studies confirmed compounds as inhibitors of both Src and Abl kinases.
• Drug-like property calculations suggest potential as therapeutic candidates.

Conclusions:

• Indole derivative C-2 exhibits potent anticancer activity against susceptible and resistant K562 cell lines.
• C-2 induces apoptosis, reinforcing its potential as a therapeutic agent for chronic myeloid leukemia.
• Indole derivatives show promise for developing novel treatments for Bcr-Abl-positive leukemias.